Table 2 Characteristics of lung cancer cases and control patients in a Spanish population
From: Polymorphism +17 C/G in Matrix Metalloprotease MMP8 decreases lung cancer risk
Variable | Cases (n = 501) n (%) | Controls (n = 510) n (%) | Pa |
|---|---|---|---|
Gender | |||
Male | 441 (88.0) | 440 (86.3) | |
Female | 60 (12.0) | 70 (13.7) | 0.406 |
Age (yrs), mean (SD) | 64.7 (11.0) | 63.6 (11.2) | 0.137 |
Smoking Status | |||
Never | 35 (7.0) | 136 (26.7) | |
Ever | 466 (93.0) | 374 (73.3) | < 0.001 |
Former | 211 (45.9) | 215 (59.9) | |
Current | 249 (54.1) | 144 (40.1) | < 0.001 |
Pack-years b, mean (SD) | 63.0 (36.5) | 39.4 (33.3) | < 0.001 |
Family history of cancer | |||
No | 262 (54.5) | 304 (60.7) | |
Yes | 219 (45.5) | 197 (39.3) | 0.049 |
Lung cancer | 57 (12.3) | 35 (7.2) | |
Other cancers | 144 (31.1) | 147 (30.5) | 0.020 |
Histological types | |||
Squamous cell carcinoma | 202 (40.3) | ||
Adenocarcinoma | 143 (28.5) | ||
Small cell carcinoma | 81 (16.2) | ||
Non-differentiated | 37 (7.4) | ||
Large cell carcinoma | 15 (3.0) | ||
Others | 8 (1.6) | ||
Clinical diagnosis | 2 (0.4) | ||
Missing | 13 (2.6) | ||
Clinical stages | |||
I | 126 (25.1) | ||
II | 28 (5.6) | ||
III | 119 (23.8) | ||
IV | 138 (27.5) | ||
LS (Limited stage) | 39 (7.8) | ||
EE (Extend stage) | 32 (6.4) | ||
Missing | 19 (3.8) |